TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03096301

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-intensity laser
Description: Laser applications will be applied as initial treatment, with 2 sessions per week. A wave length of 780 nm, with an energy density of 25 J/cm2, a power of 50 mW and power density of 1.25 W/cm2, will be used for a duration of 20 seconds per point, resulting in a total energy of 1J per point. The laser will be applied at each point, using a conventional tip in contact with the skin, thus considering an area of 0.04 cm2

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: occlusal plates
Description: The group undergoing treatment with occlusal plates will be instructed to use the device during sleep, 8 hours per night, for a period of 12 months. The plates will be made following the principles established by Okenson (1998).~Participants will be molded with alginate to obtain models. In the upper model, a 2 mm acetate plate will be made, to be later replaced with acrylic resin (STRINI et al., 2009), and these plates will be adjusted in centric relation, to promote occlusal stability and disocclusion guide.~Weekly follow-up and adjustments will be performed during the evaluation period, until the completion of treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo
Description: For the placebo group, all the measures described for the group 1 (LIL) will be adopted, however the laser equipment will remain switched off.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: For the placebo group, all the measures described for the group 1 (LIL) will be adopted, however the laser equipment will remain switched off.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For the placebo group, all the measures described for the group 1 (LIL) will be adopted, however the laser equipment will remain switched off.
Study: NCT03847623

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Natural compound, active ingredient of turmeric, in bi-daily dosing

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets at bi-daily dosing
Study: NCT04230460

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cannabis (THC) (Inhaled) Placebo
Description: Cannabis vapor is produced from 500 mg of dried plant material (placebo) (0% THC). Participants will inhale ad libitum over 10 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis (High% THC) (Inhaled)
Description: Cannabis vapor is produced from 500 mg of dried plant material (7.5% THC). Participants will inhale ad libitum over 10 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis (Very High% THC) (Inhaled)
Description: Cannabis vapor is produced from 500 mg of dried plant material (12.5% THC). Participants will inhale ad libitum over 10 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol (oral)
Description: Subjects will be dosed to achieve a 0.05% Blood Alcohol Concentration (BAC), so the amount of alcohol consumed will be calculated to produce a peak BAC of 0.065%. Subjects will be served three equal-sized drinks, 10-minutes apart, and be instructed to pace each drink evenly over the 10-minute period.
Study: NCT04062435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drop application in the inferior fornix
Description: See Arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drop application on the cornea
Description: See Arms
Study: NCT02779023

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavior Therapy for Insomnia (CBT-I)
Study: NCT04665310

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Envarsus XR
Description: tacrolimus, extended-release tablets, a calcineurin inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Envarsus XR
Description: tacrolimus, extended-release tablets, a calcineurin inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Envarsus XR
Description: tacrolimus, extended-release tablets, a calcineurin inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Envarsus XR
Description: tacrolimus, extended-release tablets, a calcineurin inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Envarsus XR
Description: tacrolimus, extended-release tablets, a calcineurin inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Envarsus XR
Description: tacrolimus, extended-release tablets, a calcineurin inhibitor
Study: NCT02454036

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BBI intervention
Description: Psychological intervention designed to reduce stress and enhance quality of life
Study: NCT00278590

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Stem Cell Transplantation
Description: Allogeneic stem cell transplantation will be performed.
Study: NCT01570595

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web-Based Tailored Smoking Cessation Intervention
Description: The Experimental group will be given an ID number to log in to the quit smoking program, and complete their first log-in with a research assistant. The online program is made up of 8 separate, weekly online sessions that take approximately 15-30 minutes to complete. The entire program is meant to be completed in 7 weeks. Participants are asked to provide an email address and/or cell phone number so reminders can be sent to complete the sessions. If participants are late completing a session, they will receive a call from clinic staff as a reminder. The standard care group will receive advice to quit, a quit-smoking brochure, and an offer of three months of nicotine replacement therapy (nicotine patches).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-Based Tailored Smoking Cessation Intervention
Description: The Experimental group will be given an ID number to log in to the quit smoking program, and complete their first log-in with a research assistant. The online program is made up of 8 separate, weekly online sessions that take approximately 15-30 minutes to complete. The entire program is meant to be completed in 7 weeks. Participants are asked to provide an email address and/or cell phone number so reminders can be sent to complete the sessions. If participants are late completing a session, they will receive a call from clinic staff as a reminder. The standard care group will receive advice to quit, a quit-smoking brochure, and an offer of three months of nicotine replacement therapy (nicotine patches).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: advice to quit, a quit-smoking brochure, and an offer of three months of nicotine replacement therapy (nicotine patches).
Study: NCT01426282

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: health education
Description: 15 minutes health education given by nurse according to  The Chinese Resident Meals Guide  , National Revision Committee of the Guidelines of Hypertension Prevention and Control in 2005 ,  Guidelines on Prevention and Treatment of Blood Lipid Abnormality in Chinese Adults  ,  Guideline for diagnosis and treatment of patients with chronic stable angina , Guideline for prevention and treatment overweight and obesity in chinese adults
Study: NCT01231243

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: in-office bleaching with/without light
Description: Two clinical sessions of tooth bleaching will be performed in each patient with a 1-week interval between them. In each session, three 15-min applications of the gel will be done using one of the two concentrations under investigation. In half of the sample of each concentration, the gel will be activated with a LED/laser device for a total of 3 min, as specified by the DMC manufacturer.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: in-office bleaching with/without light
Description: Two clinical sessions of tooth bleaching will be performed in each patient with a 1-week interval between them. In each session, three 15-min applications of the gel will be done using one of the two concentrations under investigation. In half of the sample of each concentration, the gel will be activated with a LED/laser device for a total of 3 min, as specified by the DMC manufacturer.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: in-office bleaching with/without light
Description: Two clinical sessions of tooth bleaching will be performed in each patient with a 1-week interval between them. In each session, three 15-min applications of the gel will be done using one of the two concentrations under investigation. In half of the sample of each concentration, the gel will be activated with a LED/laser device for a total of 3 min, as specified by the DMC manufacturer.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: in-office bleaching with/without light
Description: Two clinical sessions of tooth bleaching will be performed in each patient with a 1-week interval between them. In each session, three 15-min applications of the gel will be done using one of the two concentrations under investigation. In half of the sample of each concentration, the gel will be activated with a LED/laser device for a total of 3 min, as specified by the DMC manufacturer.
Study: NCT00119262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: pegfilgrastim
Description: Given SC

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Undergo radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Description: Given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamoxifen citrate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aromatase inhibition therapy
Description: Receive aromatase inhibition therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aromatase inhibition therapy
Description: Receive aromatase inhibition therapy
Study: NCT00423852

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study: NCT00363194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib (GW786034)
Description: Pazopanib (GW786034)
Study: NCT05824390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab group
Description: Rituximab is a human-mouse chimeric monoclonal antibody specifically targeting B cell surface antigen CD20. CD20 may act as a calcium channel to play a certain signal role and participate in the regulation of B cell maturation and differentiation. Once combined with CD20, RTX consumed CD20 + B fines through antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity and direct induction of apoptosis. Recent studies have shown that B cell depletion therapy has a certain effect on many autoantibodies-mediated kidney diseases ( such as membranous nephropathy, lupus nephritis, etc. ). Therefore, rituximab combined with CD20 antigen on the surface of B cells can exhaust B cells that produce antibodies and play a therapeutic role by reducing antibody production, so this therapy also has potential therapeutic value for IgAN patients.
Study: NCT00572624

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Participants attended 20 group behavioral modification sessions led by a behaviorist, a registered dietician, and a physical therapist. The meal plans ranged from 1200 to 1500 kilocalories per day, depending on subject sex and BMI, and were designed to achieve ≤1% body weight loss/week. Participants completed daily food records, and were taught a variety of weight management skills. The exercise component included strength, flexibility, balance, and endurance instruction, gradually increasing to 30 minutes of exercise 5 days/week.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric bypass surgery
Description: The same surgeon performed all bypass procedures using standard techniques. A small (\~20 ml) proximal gastric pouch was created by stapling the stomach, and a 75-cm Roux-en-Y limb was constructed by transecting the jejunum distal to the ligament of Treitz, and creating a jejunojejunostomy 75 cm distal to the transection.
Study: NCT03692221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC Treatment group 1 (low dose)
Description: Autologous Bone Marrow Derived Mesenchymal Stem Cells (MSC) - A one time injection of 1-2 ml of a 4 x 106/ml concentration solution
Study: NCT02402465

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be treated by placebo
Study: NCT04456868

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electroencephalogram
Description: Electroencephalogram will be done for P300 wave assessment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Electroencephalogram
Description: Electroencephalogram will be done for P300 wave assessment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Electroencephalogram
Description: Electroencephalogram will be done for P300 wave assessment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Electroencephalogram
Description: Electroencephalogram will be done for P300 wave assessment
Study: NCT02402465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Description: Patients will receive fluticasone nasal spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone/Azelastine nasal spray
Description: Patients will receive Dymista nasal spray

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nasal Allergen Challenge
Description: All subjects will receive a nasal challenge with allergen to mimick an allergic response and allow the investigation of the different drug effects on that response. Allergen extracts will be used as sprays into the nasal cavity. The extracts are approved by FDA for skin testing or desensitization therapy and an IND was obtained to allow intranasal administration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nasal Allergen Challenge
Description: All subjects will receive a nasal challenge with allergen to mimick an allergic response and allow the investigation of the different drug effects on that response. Allergen extracts will be used as sprays into the nasal cavity. The extracts are approved by FDA for skin testing or desensitization therapy and an IND was obtained to allow intranasal administration

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Nasal Allergen Challenge
Description: All subjects will receive a nasal challenge with allergen to mimick an allergic response and allow the investigation of the different drug effects on that response. Allergen extracts will be used as sprays into the nasal cavity. The extracts are approved by FDA for skin testing or desensitization therapy and an IND was obtained to allow intranasal administration
Study: NCT01599377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib 10 mg
Description: Cohort 1 will consist of 2 periods and 2 sequences. Subjects will be randomized to one of the 2 sequences. In sequence 1, subjects will receive a 10 mg tofacitnib tablet under fasting conditions in period 1, followed by a 10 mg tofacitinib capsule in fasting conditions in period 2. In sequence 2, the treatments will be reversed for period 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib 5 mg
Description: Cohort 2 will consist of 2 periods and 2 sequences. A total of 24 healthy subjects will be enrolled for this cohort. Subjects will be randomized to one of the 2 sequences. In sequence 1, subjects will receive a 5 mg tablet under fasting conditions in period 1, followed by a 5 mg capsule in fasting conditions in period 2. In sequence 2, the treatments will be reversed for period 1 and 2.
Study: NCT02615834

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gentle chest pressure
Description: Gentle pressure on the patient's right chest will be applied to achieve 12 breaths per minute.
Study: NCT02105727

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-based salt reduction
Study: NCT00317603

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous, Lethally Irradiated Breast Cancer Cells
Description: Vaccine will be administered on days 1, 8, 15, 29 and then every 2 weeks until the supply of vaccine runs out
Study: NCT05262465

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: microtransplantation, HLA-mismatched donor peripheral stem cell infusion
Description: HLA-mismatched donor peripheral stem cell infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: azacytidine 50-75mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax 100-300mg/d ×3d，400mg 4-28d
Study: NCT02720081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1029 150 mg
Description: 150 mg tablet administered orally, once a day (QD), at bedtime

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MK-1029 Matching-image Placebo
Description: Matching-image placebo tablet administered orally, QD, at bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg
Description: 10 mg tablet administered orally, QD, at bedtime

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Montelukast 10 mg
Description: 10 mg tablet administered orally, QD, at bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol/Salbutamol 90 mcg - 100 mcg per inhalation
Description: 1 or 2 inhalations 4 times a day (QID) as needed (PRN) as a Rescue Medication

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albuterol/Salbutamol 90 mcg - 100 mcg per inhalation
Description: 1 or 2 inhalations 4 times a day (QID) as needed (PRN) as a Rescue Medication
Study: NCT01620398

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BALANCE

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control diet
Description: Participants will be encourage to follow a generalized diet counseling prepared by dietitians based on low fat, low energy, low sodium and low cholesterol diets. They will receive a common folder composed by lists of foods that should be preferred or avoided. For example, avoidance of ultra processed foods, preference for boiled and baked foods rather than fried foods and recommendation of having at least five meals a day. This folder is equivalent of several that are given on ambulatories or hospital of Brazilian public health.
Study: NCT04632797

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hilotherm Chemo Care
Description: Application of Hilotherm Chemo Care gloves for constant cryotherapy during chemotherapy application.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hilotherm Chemo Care
Description: Application of Hilotherm Chemo Care gloves for constant cryotherapy during chemotherapy application.
Study: NCT00586742

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: labral repair
Description: labral repair with suture anchors

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: biceps tenodesis
Description: biceps tenodesis with suture anchor

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: diagnostic arthroscopy
Description: diagnostic arthroscopy
Study: NCT03738254

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Guardians: A smartphone game
Description: The Guardians is a mix of two popular game genres: idle games (a game that doesn't require constant player input in order to progress in the game, but often progresses exponentially in response to a few user inputs, e.g., Cookie Clicker and Adventure Capitalist) and pet collection games (a game where the player seeks to collect all of the pets in a set, e.g., Pokemon or Neko Atsume). The game gives the player an in-game reward for completing a survey.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paper Survey
Description: Paper version of daily survey

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Survey
Description: Electronic version of daily survey administered via a smartphone app.
Study: NCT00439647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid 5 mg iv
Description: Zoledronic acid 5 mg iv given once a year.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intravenous (i.v.) once a year